EDIT - Editas Medicine Inc. (EDIT) Leerink Partners Global Biopharma Conference (Transcript)
2024-03-12 15:56:10 ET
Editas Medicine, Inc. (EDIT)
Leerink Partners Global Biopharma Conference
March 12, 2024, 10:40 AM ET
Company Participants
Gilmore O'Neill - CEO
Erick Lucera -
Conference Call Participants
Mani Foroohar - Leerink
Presentation
Mani Foroohar
Good morning, everyone. Welcome back to the 2024 Global Biopharma Conference, Inaugural Miami Conference. So welcome everybody down. I am Mani Foroohar, Senior Analyst Genetic Medicines. And I'm very fortunate to be hosting the team from Editas Medicine. How are you doing?
Gilmore O'Neill
Good, thank you. Good morning to you. A little cool. It seems cooler down here than it does in Boston. I don't know why, but it does.
Question-and-Answer Session
Q - Mani Foroohar
It might be because the air conditioning is running, at a completely climate irresponsible level. But I think that's an endemic problem. Gilmore, we'll start with you. Obviously, there's been a lot of excitement around gene editing, gene therapy, base editing, genetic medicines, broadly speaking, as we've entered the commercial arena for, we'll say, therapies of curative intent. The word cure itself, I know, has a lot of baggage. Let's talk a little about how you see the reimbursement dynamic around one-time therapies, for severe diseases, the drive value over many years, but have value that can be a little harder to exactly define, because you're having to make sort of assumptions around utilization, reimbursement, future value. Tell me a little bit about where you see that world and how sophisticated you see your counterparts in payer land, your experience - your early conversations, and the conversations your counterparts are having, about how to value a one-time therapy for something very severe that's still kind of a transplant medicine?...
Editas Medicine, Inc. (EDIT) Leerink Partners Global Biopharma Conference (Transcript)